Holen Sie sich die Stockscreener-App
51.83
0.02%
-0.01
Handel nachbörslich:
51.83
Schlusskurs vom Vortag:
$51.84
Offen:
$51.97
24-Stunden-Volumen:
2.07M
Relative Volume:
0.72
Marktkapitalisierung:
$9.91B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-21.51
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
-1.41%
1M Leistung:
+8.54%
6M Leistung:
+54.53%
1J Leistung:
+68.99%
1-Tages-Spanne:
$50.49
$52.48
1-Wochen-Bereich:
$49.75
$52.84
52-Wochen-Spanne:
$21.72
$52.84
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
51.83 | 9.56B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Pharma (BBIO) Receives a Rating Update from a Top Analyst - The Globe and Mail
BridgeBio Pharma Inc. stock momentum explainedInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Applying Elliott Wave Theory to BridgeBio Pharma Inc.July 2025 Action & Pattern Based Trade Signal System - Newser
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - The Manila Times
BridgeBio Pharma (BBIO) Rating Reiterated as 'Buy' by HC Wainwright & Co. | BBIO Stock News - GuruFocus
Phase 3 Trial Update: BridgeBio's Breakthrough ADH1 Drug Encaleret Featured in NIH Expert Webinar - Stock Titan
When is the best time to exit BridgeBio Pharma Inc.Earnings Performance Report & Stepwise Entry and Exit Trade Signals - Newser
What candlestick patterns are forming on BridgeBio Pharma Inc.Market Movement Recap & Expert Approved Momentum Ideas - Newser
Is BridgeBio Pharma Inc. a good ESG investmentProfit Target & Free Weekly Watchlist of Top Performers - khodrobank.com
Chart based analysis of BridgeBio Pharma Inc. trendsPrice Action & Risk Controlled Daily Trade Plans - Newser
Market reaction to BridgeBio Pharma Inc.’s recent newsPortfolio Risk Summary & Real-Time Market Trend Scan - Newser
Backtesting results for BridgeBio Pharma Inc. trading strategies2025 Buyback Activity & Weekly Chart Analysis and Guides - Newser
Strategies to average down on BridgeBio Pharma Inc.2025 Top Decliners & Proven Capital Preservation Methods - Newser
BridgeBio Pharma Inc. recovery potential after sell off2025 Key Highlights & Stepwise Swing Trade Plans - Newser
News impact scoring models applied to BridgeBio Pharma Inc.Trade Exit Summary & Reliable Price Breakout Alerts - Newser
What’s the analyst consensus on BridgeBio Pharma Inc.2025 Top Decliners & Stepwise Swing Trade Plans - khodrobank.com
Can BridgeBio Pharma Inc. withstand a market correctionMarket Sentiment Report & Entry and Exit Point Strategies - khodrobank.com
Using RSI to spot recovery in BridgeBio Pharma Inc.2025 Dividend Review & Long-Term Growth Portfolio Plans - Newser
Short Interest Drops in BridgeBio Pharma Inc. After RallyMarket Performance Report & Weekly High Momentum Picks - beatles.ru
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism - The Manila Times
BridgeBio Pharma Presents Phase 2 Data on Post-Surgical Hypoparathyroidism and Skeletal Dysplasia at ASBMR Annual Meeting 2025 - Quiver Quantitative
New Treatment Hope: BridgeBio's Encaleret Shows Promise in Post-Surgical Hypoparathyroidism Phase 2 Trial - Stock Titan
Is it time to cut losses on BridgeBio Pharma Inc.Trade Volume Report & Long-Term Safe Investment Ideas - Newser
What’s next for BridgeBio Pharma Inc. stock priceLayoff News & Community Verified Watchlist Alerts - Newser
Published on: 2025-09-02 04:42:43 - Newser
Tick level data insight on BridgeBio Pharma Inc. volatilityEarnings Overview Summary & Weekly High Return Opportunities - Newser
Is BridgeBio Pharma Inc. a defensive stock2025 Breakouts & Breakdowns & Verified Short-Term Plans - خودرو بانک
BridgeBio Pharma: Promising Phase 3 Data and Strong Financial Performance Justify Buy Rating - TipRanks
Is BridgeBio Pharma Inc. stock a top performer YTDMarket Performance Summary & Entry Point Strategy Guides - khodrobank.com
Tools to monitor BridgeBio Pharma Inc. recovery probabilityPortfolio Risk Report & Daily Chart Pattern Signal Reports - Newser
How does BridgeBio Pharma Inc. score in quality rankingsJuly 2025 Sector Moves & Expert-Curated Trade Recommendations - khodrobank.com
BridgeBio Pharma Inc. stock volume spike explained2025 Pullback Review & Pattern Based Trade Signal System - Newser
Reversal indicators forming on BridgeBio Pharma Inc. stockQuarterly Trade Summary & Free Verified High Yield Trade Plans - Newser
What to do if you’re stuck in BridgeBio Pharma Inc.July 2025 Outlook & Daily Chart Pattern Signals - Newser
Trendlines Converge — Decision Point for BridgeBio Pharma Inc.2025 Dividend Review & Safe Capital Growth Plans - beatles.ru
BridgeBio says new Attruby data adds to benefit in ATTR-CM - MSN
Using fundamentals and technicals on BridgeBio Pharma Inc.Portfolio Performance Summary & Fast Moving Stock Trade Plans - Newser
Published on: 2025-08-31 13:32:00 - Newser
Analyzing recovery setups for BridgeBio Pharma Inc. investors2025 Fundamental Recap & Daily Stock Momentum Reports - Newser
BridgeBio Pharma Inc. Rebounds From Oversold Zone — Now What getLinesFromResByArray error: size == 0 - newsyoung.net
Here’s What Wall Street Thinks About BridgeBio Pharma (BBIO) - MSN
BridgeBio's Attruby Shows Significant Reduction in Cardiovascular Mortality in ATTR-CM Patients - AInvest
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bridgebio Pharma Inc-Aktie (BBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Aug 20 '25 |
Sale |
48.82 |
26,156 |
1,276,927 |
223,090 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):